Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Athersys and Aethlon Medical Presenting at the 2010 Spring Break for Wall Street Growth & Value Equity Conference



Athersys and Aethlon Medical Presenting at the 2010 Spring Break for Wall
Street Growth & Value Equity Conference

FORT LAUDERDALE, Fla., March 4, 2010 (GLOBE NEWSWIRE) -- Medical Science and
Technology bring Aethlon Medical (OTCBB:AEMD) and Athersys (Nasdaq:ATHX) to
Spring Break for Wall Street.

The event is being hosted by LDV Capital Management and will be from 4:00 p.m.
to 9:00 p.m. at the Sheraton Suites Cypress Creek Fort Lauderdale Hotel, 555
NW 62^nd Street, Fort Lauderdale, Florida 33309.

Aethlon Medical (OTCBB:AEMD):  Will present at 6:10 p.m. in Salon 6.

Aethlon Medical, Inc. creates diagnostic and therapeutic device solutions for
infectious diseases and cancer. The lead product, the Hemopurifier(R) is the
first-in-class medical device to selectively capture circulating viruses and
immunosuppressive proteins prior to cell and organ infection. Human studies
have documented the ability of our Hemopurifier(R) to reduce viral load in
patients infected with Hepatitis-C virus (HCV) and the Human Immunodeficiency
Virus (HIV).   For more information see www.aethlonmedical.com

Athersys (Nasdaq:ATHX): Will present at 5:35 p.m. in Salon 4.

Athersys is a clinical stage biopharmaceutical company engaged in the
discovery and development of therapeutic product candidates designed to extend
and enhance the quality of human life. The Company is developing MultiStem(R),
a patented, adult-derived "off-the-shelf" stem cell product platform for
multiple disease indications, including damage caused by myocardial
infarction, bone marrow transplantation and oncology treatment support,
ischemic stroke, and inflammatory bowel disease. The Company is also
developing a portfolio of other therapeutic programs, including orally active
pharmaceutical product candidates for the treatment of metabolic and central
nervous system disorders. For more information, see www.athersys.com.

Other conference companies presenting include: Aethlon Medical (OTCBB:AEMD),
Athersys (Nasdaq:ATHX), Aurizon Mines (AMEX:AZK), Bluefire Energy
(OTCBB:BFRE), Claude Resources (AMEX:CGR), Converted Organics (Nasdaq:COIN),
Data Storage Corp. (OTCBB:DTST), Element 21 Golf Co. (OTCBB:ETGF), Fronteer
Gold (AMEX:FRG), Heska Corporation (Nasdaq:HSKA), Homeowners Choice
(Nasdaq:HCII), Lucas Energy (AMEX:LEI), Nevada Gold & Casinos,
Inc. (AMEX:UWN), Next 1 Interactive (OTCBB:NXOI), Optimized Transportation
Management (OTCBB:OPTZ), Pyrolyzer, LLC, Rogers Oil and Gas Corp., Rubicon
Minerals (AMEX:RBY), Seafarer Exploration Corp. (OTCBB:SFRX), SMF Energy
Corporation (Nasdaq:FUEL), and T3 Motion, Inc. (OTCBB:TMMM).

To expedite registration, call LDV Capital Management at: 954-746-3117,
www.LdvCapitalManagement.com, or email Jim@LdvCapitalManagement.com.

DISCLAIMER: LDV Capital Management is a Registered Investment Advisory firm
licensed with the State of Florida. The information herein is not a
solicitation to invest, but simply information compiled from company press
releases and company public information. Information is believed to be
reliable, but makes no representation to its accuracy or completeness. LDV
does not recommend, warrant, or guarantee the success of any action taken in
reliance on statements made in this news release or by any company
presentations at the Conference. Due-diligence and professional advice should
be sought before making any investment decisions. As in any investment, risks
apply, where part of or all investment capital can be lost. Presenting
Companies paid a sponsorship fee to present at the Conference. Scheduled
times, agendas, and presenters are subject to change. LDV, nor any of its
principles or employees do not hold any stock positions in any of the
companies mentioned above.

CONTACT:  LDV Capital Management
          954-746-3117
          Jim@LdvCapitalManagement.com
          www.LdvCapitalManagement.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement